Drugs for Heritable Pulmonary Arterial Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 123)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Iron |
Approved, Experimental |
Phase 4 |
|
15438-31-0, 7439-89-6 |
27284 23925 |
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
Ancor B
Ancor en 80/150
armco Iron
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
ATW 230
ATW 432
C00023
C3518_SIAL
C3518_SIGMA
Carbonyl iron
CCRIS 1580
CHEBI:18248
CID23925
Copy Powder CS 105-175
D007501
DB01592
Diseases (animal), iron overload
Diseases, iron overload
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Ed-In-Sol
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
Eisen
Electrolytic iron
F 60 (metal)
Fe
FE
FE (II) ion
Fe(2+)
Fe(II)
Fe1+
Fe2+
Fe-40
|
fer
Feronate
Ferretts
Ferro-Caps
Ferro-Time
Ferrous ion
ferrous iron
Ferrousal
Ferrovac e
Ferrovac E
Ferrum
Ferrum metallicum
FT 3 (element)
GS 6
Hematite
Hemocyte
HF 2 (element)
hierro
Hierro
HL (iron)
Hoeganaes ATW 230
Hoeganaes EH
HQ (metal)
HS (iron)
HS 4849
HSDB 604
Infed
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron ion(2+)
Iron monocation
Iron powder
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(2+)
Iron(2+) ion
Iron(II) ion
Iron(III) nitrate solution
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
Iron, ion (Fe2+)
Iron, reduced
Limonite
LOHA
LS-3196
Magnetite
Malleable iron
Metopirone
Metyrapone
MolPort-003-925-001
NC 100
PZh1M1
PZh-1M3
PZh-2
PZh2M
PZH2m
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
PZHO
Reduced iron
Remko
Siderol
Suy-b 2
SUY-B 2
Taconite
UNII-E1UOL152H7
Venofer
Vitedyn-Slo
Wrought iron
Yieronia
|
|
2 |
|
Ambrisentan |
Approved, Investigational |
Phase 4 |
|
177036-94-1 |
6918493 |
Synonyms:
(+-)-(2S)-2-((4,6-Dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid
(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy- 3,3-diphenylpropanoic acid
177036-94-1
2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid
2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenyl-propanoic acid
2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid
AC1L53VT
Ambrisentan
Ambrisentan [INN]
Benzenepropanoic acid, .alpha.-[(4,6-dimethyl-2-pyrimidinyl)oxy]-.beta.-methoxy-.beta.-phe
BSF 208075
BSF208075
BSF-208075
C467894
CHEBI:205299
CHEMBL302753
|
CID197712
Gilead brand of ambrisentan
I06-2077
Letairis
LS-186563
LS-187364
LU 208075
LU208075
LU-208075
MLS001195278
MolPort-002-945-567
NCGC00160662-01
SMR000502713
ST51051295
STK097095
UNII-HW6NV07QEC
|
|
3 |
|
Silver sulfadiazine |
Approved, Vet_approved |
Phase 4 |
|
22199-08-2 |
441244 |
Synonyms:
(4-Amino-N-pyrimidin-2-ylbenzenesulphonamidato-NN,O1)silver
22199-08-2
481181_ALDRICH
4-Amino-N-(2-pyrimidinyl)benzenesulfonamide silver salt
4-amino-N-pyrimidin-2-ylbenzenesulfonamide
Abbott Brand of Silver Sulfadiazine
AC-19319
AC1L1KQS
AC1L9ATF
AC1L9Q6O
AC1NUR63
AC1O8LAG
AC-3535
AKOS005111099
AKOS005111434
Aldo Brand of Silver Sulfadiazine
ARONIS23842
Benzenesulfonamide, 4-amino-N-2-pyrimidinyl-, monosilver(1+) salt
Benzenesulfonamide,4-amino-N-2-pyrimidinyl-, silver complex
Brandiazin
C10H9N4O2S.Ag
CHEBI:9142
CHEMBL1200766
CID11947738
CID31011
CID441244
CID452254
CID5459124
D00433
D012837
DB05245
Dermazin
Dermazine
EINECS 244-834-5
Flamazine
Flammazine
Geben
I06-0145
I06-145
LS-147839
Major Brand of Silver Sulfadiazine
medphano Brand of Silver Sulfadiazine
MLS000069662
MolPort-003-934-423
MolPort-003-986-619
MolPort-006-395-987
Monarch Brand of Silver Sulfadiazine
N(sup 1)-2-Pyrimidinylsulfanilamide monosilver(1+) salt
N1-2-Pyrimidinylsulfanilamide monosilver(1+) salt
NSC 625324
NSC625324
|
Par Brand 1 of Silver Sulfadiazine
Par Brand 2 of Silver Sulfadiazine
Par Brand 3 of Silver Sulfadiazine
Pharmascience Brand of Silver Sulfadiazine
Rhone Poulenc Rorer Brand of Silver Sulfadiazine
Rhone-Poulenc Rorer Brand of Silver Sulfadiazine
S0595
Sherwood Brand of Silver Sulfadiazine
Sicazine
Silbertone
Sildaflo
Silvadene
Silvadene (TN)
Silvederma
silver
silver (4-aminophenyl)sulfonyl-pyrimidin-2-ylazanide
silver 4-amino-N-pyrimidin-2-ylbenzenesulfonamide
silver sulfadiazinate
Silver sulfadiazinate
silver sulfadiazine
Silver sulfadiazine
Silver Sulfafdiazine
Silver sulphadiazine
silver(1+) [(4-aminophenyl)sulfonyl](pyrimidin-2-yl)azanide
Silver(I) sulfadiazine
Smith & Nephew Brand of Silver Sulfadiazine
SMR000059233
Solvay Brand of Silver Sulfadiazine
SSD
SSD (1% Silver Sulfadiazine Cream USP)
SSD AF
STL069502
Sulfadiazin silber
Sulfadiazin, silbersalz
Sulfadiazine silver
SULFADIAZINE SILVER
Sulfadiazine silver (JP15)
Sulfadiazine silver salt
Sulfadiazine silverSilvadene
Sulfadiazine, silver
Sulfadiazine, silver (USP)
Sulfadiazine, Silver [USAN]
Sulfafdiazine, Silver
Sulfanilamide, N(sup 1)-2-pyrimidinyl-, monosilver(1+) salt
Sulfanilamide,N1-2-pyrimidinyl-, monosilver(1+) salt
Sulfargen
Thermazene
TL8001845
UNII-W46JY43EJR
Zenith Brand of Silver Sulfadiazine
|
|
4 |
|
Epoprostenol |
Approved |
Phase 4 |
|
35121-78-9, 61849-14-7 |
5282411 5280427 |
Synonyms:
(5E)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
(5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
(5Z)-5-[(4R,5R)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
(5Z,13E)-(15S)-6,9a-Epoxy-11a,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9a-Epoxy-11a,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9-alpha-Epoxy-11-alpha,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E)-(15S)-6,9-alpha-Epoxy-11-alpha,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E)-(15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E)-(15S)-6,9α-epoxy-11α,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9α-epoxy-11α,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E,15S)-6,9a-Epoxy-11a,15-dihydroxyprosta-5,13-dienoate
(5Z,13E,15S)-6,9a-Epoxy-11a,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E,15S)-6,9alpha-epoxy-11alpha,15-dihydroxyprosta-5,13-dienoic acid
(5Z,9a,11a,13E,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oate
(5Z,9a,11a,13E,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oic acid
(5Z,9alpha,11alpha,13E,15S)-11,15-dihydroxy-6,9-epoxyprosta-5,13-dien-1-oic acid
(5Z,9alpha,11alpha,13E,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oate
(5Z,9alpha,11alpha,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid
(5Z,9alpha,11alpha,13E,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oic acid
(5Z,9α,11α,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oate
(5Z,9α,11α,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid
(5Z,9α,11α,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oic acid
(Z)-(3aR,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S)-3-hydroxy-1-octenyl)-2H-cyclopenta(b)furan-delta(sup 2,delta)-valeric acid
136626-78-3
35121-78-9
5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
5-[5-hydroxy-4-(3-hydroxyoct-1-enyl)-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
6,9-alpha-Epoxy-11-alpha,15(S)-dihydroxyprosta-5(Z),13(E)-dien-1-oic acid
61849-14-7
63748-50-5
63859-31-4
AC1L18LX
AC1L3FZB
AC1NQX0K
AC1NR00P
AC1O51WG
AC1O5HI7
AR-1I7150
BIDD:GT0514
Bio2_000216
Bio2_000696
BRD-K64054020-001-02-7
BRN 1690090
BSPBio_001496
C01312
CHEBI:15552
CHEMBL1139
CHEMBL307845
CID114805
CID11969614
CID159
CID5280427
CID5282411
|
CID6434194
CID6450541
CID9864371
CID9975312
D00106
DB01240
Epoprostanol
epoprostenol
Epoprostenol
Epoprostenol (TN)
Epoprostenol (USAN/INN)
Epoprostenol [USAN:INN]
Epoprostenol sodium
Epoprostenol sodium salt, (5Z,9alpha,11alpha,13E,15S)-isomer
Epoprostenolum
Epoprostenolum [INN-Latin]
Flolan
HMS1791K18
HMS1989K18
IDI1_033966
KBio2_000216
KBio2_002784
KBio2_005352
KBio3_000431
KBio3_000432
KBioGR_000216
KBioSS_000216
KB-IV-24
LMFA03010087
LS-125828
NCGC00161285-01
NCGC00161285-02
NCGC00161285-03
PDSP1_001721
PDSP2_001704
PGI(sub 2)
PGI2
PG-I2
PGX
prostacyclin
Prostacyclin
Prostacyclin I2
Prostacycline
Prostacyclins
Prostaglandin I
Prostaglandin I(2)
prostaglandin I2
Prostaglandin I2
Prostaglandin X
Prostaglandins X
SMP2_000227
TRY 200
Try-200
U 53,217
U-53217
UNII-DCR9Z582X0
Vasocyclin
|
|
5 |
|
Sodium citrate |
Approved, Investigational |
Phase 4 |
|
68-04-2 |
|
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
|
Sodium citrate, anhydrous
Sodium citrate,anhydrous
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
6 |
|
Macitentan |
Approved |
Phase 4 |
|
441798-33-0 |
|
Synonyms:
|
7 |
|
Tadalafil |
Approved, Investigational |
Phase 4 |
|
171596-29-5 |
110635 |
Synonyms:
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12AR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
171596-29-5
1xoz
351, IC
6-benzo[1,3]DIOXOL-5-yl-2-methyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
AC1L380B
Acdirca
Adcirca
ADCIRCA
C429886
CHEBI:41488
CHEMBL779
Cialis
Cialis (TN)
Cialis, GF 196960, IC 351, ICOS 351, Tadalafil
CID110635
CPD000466321
D02008
DB00820
FT-0080116
GF 196960
GF-196960
HMS2051N17
|
HSDB 7303
IC 351
Ic351
IC-351
ICOS 351
KS-1117
Lilly brand of tadalafil
LS-186558
LS-187015
LS-187770
MLS000759426
MLS001165782
MLS001195644
MLS001424132
MolPort-002-885-864
S1512_Selleck
SAM001246586
SMR000466321
Tadalafil
Tadalafil (JAN/USAN/INN)
Tadalafil [USAN]
Tadalafilo
Tadanafil
UNII-742SXX0ICT
ZINC03993855
|
|
8 |
|
Spironolactone |
Approved |
Phase 4 |
|
52-01-7, 1952-01-7 |
5833 |
Synonyms:
4-18-00-01601 (Beilstein Handbook Reference)
496916-40-6
4-Pregnen-21-oic acid-17alpha-ol-3-one-7alpha-thiol gamma-lactone 7-acetate
52-01-7
7alpha-(acetylsulfanyl)-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone
7-alpha-Acetylthio-3-oxo-17-alpha-pregn-4-ene-21,17-beta-carbolactone
AB00513806
Abbolactone
AC1L1L8Q
AC-4214
Acelat
Aldace
Aldactazide
Aldactide
Aldactone
Aldactone (TN)
Aldactone a
Aldactone A
Alderon
Aldopur
Almatol
Alphapharm brand OF spironolactone
Alphapharm Brand of Spironolactone
Alpharma brand OF spironolactone
Alpharma Brand of Spironolactone
Alter brand OF spironolactone
Alter Brand of Spironolactone
Altex
Aquareduct
Ashbourne brand OF spironolactone
Ashbourne Brand of Spironolactone
Azupharma brand OF spironolactone
Azupharma Brand of Spironolactone
betapharm Brand of Spironolactone
Betapharm brand OF spironolactone
BIDD:PXR0071
BPBio1_000194
BRD-K90027355-001-03-4
BRN 0057767
BSPBio_000176
C07310
C24H32O4S
Cardel brand OF spironolactone
Cardel Brand of Spironolactone
CHEBI:428201
CHEBI:45692
CHEBI:9241
CHEMBL1393
CID5833
CPD000471892
ct Arzneimittel Brand of Spironolactone
CT Arzneimittel brand OF spironolactone
ct-Arzneimittel Brand of Spironolactone
CT-Arzneimittel brand OF spironolactone
D00443
D013148
DB00421
Deverol
dexo Brand OF spironolactone
Dexo Brand of Spironolactone
Diatensec
Dira
Duraspiron
EINECS 200-133-6
Espironolactona
Espironolactona [INN-Spanish]
Espironolactona alter
Espironolactona Alter
Espironolactona mundogen
Espironolactona Mundogen
Euteberol
Flumach
Frumikal
Generosan brand OF spironolactone
Generosan Brand of Spironolactone
HMS1568I18
HMS2090N21
Hormosan brand OF spironolactone
Hormosan Brand of Spironolactone
HSDB 3184
I06-1970
Jenapharm brand OF spironolactone
Jenapharm Brand of Spironolactone
Jenaspiron
Lacalmin
Lacdene
Laractone
LS-118614
LT00772287
Mayoly-spindler brand OF spironolactone
Mayoly-Spindler Brand of Spironolactone
Melarcon
Merck dura brand OF spironolactone
Merck dura Brand of Spironolactone
MLS001074672
MLS001333253
MLS001333254
|
MLS002153245
MLS002207058
Mundogen brand OF spironolactone
Mundogen Brand of Spironolactone
NCGC00164397-01
NCGC00164397-02
Nefurofan
novo Spiroton
Novo Spiroton
Novopharm brand OF spironolactone
Novopharm Brand of Spironolactone
novo-Spiroton
NovoSpiroton
Novo-Spiroton
NSC 150399
NSC150399
Osyrol
Pfizer brand OF spironolactone
Pfizer Brand of Spironolactone
Pharmafrid brand OF spironolactone
Pharmafrid Brand of Spironolactone
Practon
Prestwick0_000128
Prestwick1_000128
Prestwick2_000128
Prestwick3_000128
Roche brand OF spironolactone
Roche Brand of Spironolactone
S0260
S3378_SIGMA
Sagisal
SAM002264648
SC 9420
SC9420
SC-9420
Searle brand OF spironolactone
Searle Brand of Spironolactone
Sincomen
SMR000471892
SNL
SPBio_002115
Spiractin
Spiresis
Spiretic
Spiridon
spiro L.U.T.
Spiro L.U.T.
spiro von ct
spiro Von CT
Spiro(17H-cyclopenta(a)phenauthrene-17,2'-(3'H)-furan)
Spiro[17H-cyclopenta[a]phenauthrene-17,2'-(3'H)-furan]
Spirobeta
Spiroctan
Spiroctanie
Spiroderm
Spirogamma
Spirolactone
Spirolakton
Spirolang
Spirolone
Spirone
spirono Isis
Spirono Isis
Spironocompren
spirono-Isis
Spirono-Isis
spironolactone
Spironolactone
Spironolactone (JP15/USP/INN)
Spironolactone [BAN:INN:JAN]
Spironolactone [INN:BAN:JAN]
Spironolactone A
Spironolactonum
Spironolactonum [INN-Latin]
spironolattone
Spironolattone
Spironolattone [DCIT]
Spironone
Spirospare
Spiro-Tablinen
Sprioderm
Supra-puren
Suracton
UNII-27O7W4T232
Uractone
Urusonin
Veroshpiron
Verospiron
Verospirone
Verospirone Opianin
von ct, spiro
Von CT, spiro
WLN: L E5 B666 FX OV MUTJ A1 E1 KSV1 F-& CT5VOXTJ
Worwag Brand of Spironolactone
Wörwag brand OF spironolactone
Xenalon
ZINC03861599
|
|
9 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-carboxy-3-hydroxypentane-1,5-dioic acid
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
|
Citretten
Citric acid monoglyceride
Citric acid monohydrate
Citric acid, anhydrous
Citric Acid, Anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
H3Cit
Hydrocerol a
Kyselina citronova
Monohydrate, citric acid
Suby g
Uralyt u
uro-Trainer
|
|
10 |
|
Tezosentan |
Investigational |
Phase 4 |
|
180384-57-0 |
|
11 |
|
Vasodilator Agents |
|
Phase 4 |
|
|
|
12 |
|
Phosphodiesterase 5 Inhibitors |
|
Phase 4 |
|
|
|
13 |
|
Sildenafil Citrate |
|
Phase 4 |
|
171599-83-0 |
|
14 |
|
Citrate |
|
Phase 4 |
|
|
|
15 |
|
Phosphodiesterase Inhibitors |
|
Phase 4 |
|
|
|
16 |
|
Chelating Agents |
|
Phase 4 |
|
|
|
17 |
|
Anticoagulants |
|
Phase 4 |
|
|
|
18 |
|
Endothelin A Receptor Antagonists |
|
Phase 4 |
|
|
|
19 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
20 |
|
Hormones |
|
Phase 4 |
|
|
|
21 |
|
Liver Extracts |
|
Phase 4 |
|
|
|
22 |
|
diuretics |
|
Phase 4 |
|
|
|
23 |
|
Diuretics, Potassium Sparing |
|
Phase 4 |
|
|
|
24 |
|
Mineralocorticoids |
|
Phase 4 |
|
|
|
25 |
|
Natriuretic Peptide, Brain |
|
Phase 4 |
|
|
|
26 |
|
Mineralocorticoid Receptor Antagonists |
|
Phase 4 |
|
|
|
27 |
|
Udenafil |
Approved, Investigational |
Phase 2, Phase 3 |
|
268203-93-6 |
6918523 |
Synonyms:
3-(1-methyl-7-oxo-3-propyl-4H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide
5-(2-Propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl)-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidine-7-one
AC1OCFJA
CID6918523
DA 8159
DA-8159
|
DA-8159udenafil
DB06267
I14-12963
Udenafil
Zidena
Zydena
|
|
28 |
|
Ranolazine |
Approved, Investigational |
Phase 3 |
|
142387-99-3, 95635-55-5 |
56959 |
Synonyms:
( -)-Ranolazine
(-)-Ranolazine
142387-99-3
95635-55-5
AC-1673
AC1L1M17
AC1Q5LYD
BRD-A97674275-001-01-9
BSPBio_002276
CHEMBL1404
CID56959
CVT-303
D05700
DB00243
Dihydrochloride, ranolazine
HCL, Ranolazine
HMS1922F16
HMS2090L09
HMS2093D21
Hydrochloride, ranolazine
I01-2008
I06-0160
KEG-1295
Latixa
Lopac0_001062
LS-187267
MLS002154149
MolPort-003-666-653
N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide
|
N-(2,6-Dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-1-piperazineacetamide
NCGC00015897-05
NCGC00095177-01
NCGC00095177-02
NCGC00095177-03
RAN D
Ran4
Ranexa
Ranexa (TN)
Ranexa, Ranolazine
Ranolazina
ranolazine
Ranolazine
RANOLAZINE
Ranolazine (USAN/INN)
Ranolazine 2HCl
Ranolazine 2HCL
Ranolazine dihydrochloride
Ranolazine Dihydrochloride
Ranolazine HCL
Ranolazine hydrochloride
Renolazine
RS-43285
RS-43285-003
S1799_Selleck
SMR000857382
SPECTRUM1505366
UNII-A6IEZ5M406
|
|
29 |
|
Iloprost |
Approved, Investigational |
Phase 3 |
|
78919-13-8 |
6443959 |
Synonyms:
(16R,S)-Methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I(sub 2)
(5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
(5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]hexahydropentalen-2(1H)-ylidene]pentanoic acid
(5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
(5Z)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
(E)-(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl)-delta(sup 2(1H),delta)-pentalenevaleric acid
(E)-5-(3aS,4R,5R,6aS)-5-Hydroxy-4((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-inyl)perhydropentalen-2-yliden)valeriansaeure
[3H]-Iloprost
73873-87-7
78919-13-8
AC1NSK5T
AC1O5JIJ
AC1O5JP3
AC1Q1J28
ACT-213105
C22H32O4
CHEMBL138694
CHEMBL236025
CHEMBL494
CID10937300
CID11639089
CID5311181
CID6435293
CID6435378
CID9885245
CID9975807
|
Ciloprost
D02721
E-1030
Endoprost
HMS2090A19
Ilomedin
Ilomedine
Iloprost
ILOPROST
Iloprost (INN)
Iloprost [BAN:INN]
Iloprost-pe
Iloprostum
Iloprostum [Latin]
L000996
LS-101845
NCGC00181784-01
PDSP2_001536
SH-401
UNII-JED5K35YGL
Ventavis
Ventavis (TN)
ZK 36374
ZK-36374
ZK-363775
|
|
30 |
|
Tyrosine |
Approved, Investigational, Nutraceutical |
Phase 2, Phase 3 |
|
60-18-4 |
6057 |
Synonyms:
(-)-a-amino-P-Hydroxyhydrocinnamate
(-)-a-amino-P-Hydroxyhydrocinnamic acid
(-)-alpha-amino-P-Hydroxyhydrocinnamate
(-)-alpha-amino-P-Hydroxyhydrocinnamic acid
(-)-alpha-Amino-p-hydroxyhydrocinnamic acid
(-)-α-amino-P-hydroxyhydrocinnamate
(−)-α-amino-p-hydroxyhydrocinnamic acid
(-)-α-amino-P-hydroxyhydrocinnamic acid
(2S)-2-amino-3-(4-Hydroxyphenyl)propanoate
(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid
(2S)-2-amino-3-(4-Hydroxyphenyl)propanoic acid
(S)-(-)-Tyrosine
(S)-2-Amino-3-(4-hydroxyphenyl)propionic acid
(S)-2-amino-3-(P-Hydroxyphenyl)propionate
(S)-2-amino-3-(P-Hydroxyphenyl)propionic acid
(S)-2-Amino-3-(p-hydroxyphenyl)propionic acid
(S)-3-(p-Hydroxyphenyl)alanine
(S)-3-(P-Hydroxyphenyl)alanine
(S)-a-amino-4-Hydroxybenzenepropanoate
(S)-a-amino-4-Hydroxy-benzenepropanoate
(S)-a-amino-4-Hydroxybenzenepropanoic acid
(S)-a-amino-4-Hydroxy-benzenepropanoic acid
(S)-alpha-amino-4-Hydroxybenzenepropanoate
(S)-alpha-amino-4-Hydroxy-benzenepropanoate
(S)-alpha-amino-4-Hydroxybenzenepropanoic acid
(S)-alpha-amino-4-Hydroxy-benzenepropanoic acid
(S)-alpha-Amino-4-hydroxybenzenepropanoic acid
(S)-Tyrosine
(S)-α-amino-4-hydroxybenzenepropanoate
(S)-α-amino-4-hydroxybenzenepropanoic acid
140-43-2
1991-85-1
25619-78-7
2-amino-3-(4-Hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoate
2-amino-3-(4-Hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoic acid
2-Amino-3-(p-hydroxyphenyl)propionic acid
2csm
3-(4-Hydroxyphenyl)-L-alanine
3-(p-Hydroxyphenyl)alanine
46209-14-7
4-hydroxy-L-phenylalanine
4-Hydroxy-L-phenylalanine
4ts1
55520-40-6
60-18-4
93829_FLUKA
93829_SIGMA
AB1002647
AC-11295
AC1L1LPI
AC1Q4U7L
AC1Q4U7M
AI3-09055
alpha-Amino-beta-(4-hydroxyphenyl)propionic acid
AR-1J3457
BB_NC-1194
Benzenepropanoate
Benzenepropanoic acid
beta-(p-Hydroxyphenyl)alanine
bmse000051
C00082
CHEBI:17895
CHEMBL925
CID6057
D00022
DB00135
|
DB03839
DD69927C-C6A8-4BC6-8E9A-0AB423B176E7
DTY
EINECS 200-460-4
FEMA No. 3736
Free-Form L-Tyrosine
HSDB 2003
H-Tyr-OH
L Tyrosine
L-(-)-Tyrosine
L-2-Amino-3-p-hydroxyphenylpropanoic acid
L-p-Tyrosine
L-P-Tyrosine
LS-2336
L-Tyrosin
L-tyrosine
L-Tyrosine (9CI)
L-Tyrosine (JAN)
L-Tyrosine hydrochloride
L-Tyrosine, homopolymer
L-Tyrosine, monomer
Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs
Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide
Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide, <3 kd fraction
Melanin synthesized from Tyr substrate catalyzed by tyrosinase, brominated with N-bromosuccinimide
Melanin synthesized from Tyr substrate catalyzed by tyrosinase, sulfonated using sulfur trioxide/DMF complex for 1.5-7 hours
MolPort-001-792-016
NCGC00159350-02
NCGC00159350-03
nchembio.105-comp1
nchembio.121-comp7
nchembio.186-comp84
nchembio.284-comp7
nchembio816-comp11
NSC 82624
Para tyrosine
Para-tyrosine
p-Tyrosine
P-Tyrosine
Rxosine
T0550
T3754_SIAL
T4321_SIAL
T4321_SIGMA
T8566_SIGMA
tirosina
Tirosina
Tirosina [Spanish]
tyr
Tyr
TYR NH3+ COOH
tyrosine
Tyrosine
TYROSINE
Tyrosine (USP/INN)
Tyrosine (VAN)
Tyrosine [USAN:INN]
Tyrosine Power
Tyrosine, L- (8CI)
Tyrosine, L isomer
Tyrosine, L-isomer
Tyrosinum
Tyrosinum [Latin]
UNII-42HK56048U
W373605_ALDRICH
Y
|
|
31 |
|
Sodium Channel Blockers |
|
Phase 3 |
|
|
|
32 |
|
Protein Kinase Inhibitors |
|
Phase 3 |
|
|
|
33 |
|
Imatinib Mesylate |
|
Phase 3 |
|
220127-57-1 |
123596 |
34 |
|
Morphine |
Approved, Investigational |
Phase 2 |
|
57-27-2 |
5288826 |
Synonyms:
(-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(-)-Heroin hydrochloride
(−)-morphine
(-)-Morphine
(-)Morphine sulfate
(5a,6a)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5a,6a)-didehydro-4,5-Epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-didehydro-4,5-Epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5R,6S,9R,13S,14R)-4,5-epoxy-N-methyl-7-morphinen-3,6-diol
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(7R,7AS,12BS)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol
4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol
47106-99-0
4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
57-27-2
6211-15-0 (sulfate (2:1) (salt) pentahydrate)
64-31-3
64-31-3 (sulfate (2:1) (salt) anhydrous)
7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol
8053-16-5
85201-37-2
Anhydrous morphine
Apokyn
Astramorph PF
Avinza
BIDD:GT0147
C01516
CCRIS 5762
CHEBI:17303
CHEMBL70
Chloride, morphine
CID5288826
Contin, MS
Cube juice
D-(-)-Morphine
DB00295
DEA No. 9300
Depodur
DepoDur
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dolcontin
Dreamer
Dulcontin
Duramorph
Duramorph PF
Duromorph
EINECS 200-320-2
Epimorph
Hard stuff
Heroin hydrochloride
Heroine hydrochloride
Hocus
|
HSDB 2134
Infumorph
Kadian
l-Morphine
LS-91748
M.O.S
Meconium
M-Eslon
MOI
MolPort-003-849-273
Morfina
Morfina [Italian]
Morphia
Morphin
Morphin [German]
Morphina
Morphina [Italian]
morphine
Morphine
Morphine [BAN]
Morphine chloride
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine sulfate
Morphine Sulfate
MORPHINE SULFATE
Morphine sulfate (2:1), anhydrous
Morphine sulfate (2:1), pentahydrate
MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE
Morphinism
Morphinum
Morphitec
Morphium
Morpho
Moscontin
Ms Contin
MS Contin
Ms Emma
MS/L
MS/S
MSIR
nchembio.317-comp1
nchembio.64-comp1
Nepenthe
NSC11441
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
Oramorph SR
Ospalivina
Rescudose
RMS
RMS Uniserts
Roxanol
Roxanol 100
Roxanol UD
SDZ 202-250
SDZ202-250
Statex
Statex Drops
Statex SR
Sulfate, morphine
UNII-76I7G6D29C
Unkie
|
|
35 |
|
Orange |
Approved |
Phase 2 |
|
|
|
36 |
|
Bisoprolol |
Approved |
Phase 1, Phase 2 |
|
66722-44-9 |
2405 |
Synonyms:
(+-)-1-((a-(2-Isopropoxyethoxy)-P-tolyl)oxy)-3-(isopropylamino)-2-propanol
(+-)-1-((alpha-(2-Isopropoxyethoxy)-p-tolyl)oxy)-3-(isopropylamino)-2-propanol
(+-)-1-((alpha-(2-Isopropoxyethoxy)-P-tolyl)oxy)-3-(isopropylamino)-2-propanol
(+-)-1-((α-(2-isopropoxyethoxy)-P-tolyl)oxy)-3-(isopropylamino)-2-propanol
(RS)-1-(4-(2-Isopropoxyethoxymethyl)phenoxy)-3-(isopropylamino)-2-propanol
1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol
1-[(1-methylethyl)amino]-3-({4-[({2-[(1-methylethyl)oxy]ethyl}oxy)methyl]phenyl}oxy)propan-2-ol
1-{4-[(2-isopropoxyethoxy)methyl]phenoxy}-3-(isopropylamino)propan-2-ol
66722-44-9
AB00514681
AC-18540
AC1L1DLQ
AKOS005110983
ARONIS24082
Bisocor
Bisoprolol
BISOPROLOL
Bisoprolol (USAN/INN)
Bisoprolol [USAN:BAN:INN]
Bisoprolol fumarate
Bisoprolol Fumarate
Bisoprolol fumarate (1:1) salt, (+-)-isomer
Bisoprolol fumarate (2:1) salt, (+-)-isomer
Bisoprolol fumerate
Bisoprolol hemifumarate
Bisoprolol Hemifumarate
Bisoprolol hydrochloride
Bisoprolol methanesulfonate salt
Bisoprolol, (-)-isomer
Bisoprolol, (+-)-isomer
Bisoprolol, fumarate (1:1) salt
Bisoprolol, fumarate (2:1) salt
Bisoprololum
Bisoprololum [Latin]
BPBio1_000373
BSPBio_000339
C06852
C18H31NO4
Cardicor
|
CHEBI:3127
CHEMBL645
CID2405
CL-297939
Concor
Condyline
Condylox
D02342
DB00612
Detensiel
Emconcor
Emcor
EMD-33512
EMD-33-512
Euradal
Fumarate, bisoprolol
Hydrochloride, bisoprolol
I01-7040
Isoten
L000133
LS-122509
Merck brand OF bisoprolol fumarate
MolPort-005-937-320
Monocor
NCGC00024868-02
NCGC00024868-03
NCGC00024868-04
NCGC00024868-05
Prestwick0_000330
Prestwick1_000330
Prestwick2_000330
Prestwick3_000330
SBB065120
Soloc
Soprol
SPBio_002260
UNII-Y41JS2NL6U
Zebeta
|
|
37 |
|
Anastrozole |
Approved, Investigational |
Phase 2 |
|
120511-73-1 |
2187 |
Synonyms:
.alpha.,alpha.,.alpha.',.alpha.'-tetramethyl-5(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
1,3-benzenediacetonitrile, a, a, a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)
120511-73-1
2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile)
2,2'-(5-(1H-1,2,4-Triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile)
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile)
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile)
2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile
a,a,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
AC1L1D49
AC-4234
alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
alpha,alpha,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
anastrazole
Anastrazole
Anastrole
Anastrozol
anastrozole
Anastrozole
Anastrozole (JAN/USAN/INN)
Anastrozole [USAN:INN:BAN]
Arimidex
Arimidex (TN)
Arimidex (Zeneca)
Arimidex, Anastrozole
Asiolex
Astra brand of anastrozole
Astra brand OF anastrozole
AstraZeneca brand of anastrozole
AstraZeneca brand OF anastrozole
C08159
C090450
C17H19N5
|
CHEBI:2704
CHEMBL1399
CID2187
CPD000466301
D00960
DB01217
HMS2052M11
HMS2089N10
HSDB 7462
I06-0021
ICI D1033
ICI-D 1033
ICI-D1033
LS-29563
MLS000759396
MLS001424217
MolPort-005-933-078
NCGC00164619-01
NSC719344
S1188_Selleck
SAM001246525
SBB066057
SMR000466301
UNII-2Z07MYW1AZ
ZD 1033
ZD1033
ZD-1033
Zeneca brand of anastrozole
Zeneca brand OF anastrozole
Zeneca ZD 1033
ZINC00000941
α,α,alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
α,α,α',α'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
|
|
38 |
|
Fulvestrant |
Approved, Investigational |
Phase 2 |
|
129453-61-8 |
104741 17756771 |
Synonyms:
(7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol
(7R,13S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
(7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
(7R,8S,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
(7α,17β)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1(10),2,4-triene-3,17-diol
129453-61-8
7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol
7alpha-(9-((4,4,5,5,5,-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol
7alpha-(9-((4,4,5,5,5-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol
7alpha-[9[(4,4,5,5,5-Pentafluropentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene-3, 17 beta diol
AC1L2XEN
AC-4693
AstraZeneca brand of fulvestrant
BIDD:ER0348
BIDD:PXR0136
C070081
C32H47F5O3S
CCRIS 8741
CHEBI:404798
CHEMBL1358
CID104741
D01161
DB00947
Faslodex
Faslodex (TN)
Faslodex(ICI 182,780)
|
Faslodex, ICI 182780, Fulvestrant
fulvestrant
Fulvestrant
Fulvestrant (JAN/USAN/INN)
Fulvestrant [USAN]
HMS2090N22
HSDB 7658
I06-1109
ICI 182,780
ICI 182,789
Ici 182780
ICI-182780
LS-64781
NCGC00164789-02
nchembio.168-comp5
nchembio.76-comp5
nchembio775-comp4
NSC719276
S1191_Selleck
UNII-22X328QOC4
ZD 182780
ZD-182780
ZD-9238
ZM 182780
ZM-182780
|
|
39 |
|
Fluoxetine |
Approved, Vet_approved |
Phase 2 |
|
54910-89-3 |
3386 |
Synonyms:
(+) or (-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine
(+) or (-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine
(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamine
(+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
(+/-)-Fluoxetine
(+/-)-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
(+/-)-N-Methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine
(+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine
(+/-)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]
(+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine
3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
52341-67-0
54910-89-3
57226-07-0
59333-67-4 (hydrochloride)
AB00053774
AC-14564
AC1L1FTH
Adofen
AKOS003663021
Animex-On
Bio-0787
Biomol-NT_000152
BPBio1_000354
BPBio1_000509
BRD-A31159102-001-01-9
BRD-A31159102-003-05-6
BSPBio_000461
BSPBio_003375
C17H18F3NO
CHEBI:5118
CHEMBL41
CID3386
D00326
DB00472
Deprex
DivK1c_006819
dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
Eufor
Floxetine
Fluctin
Fluoxeren
Fluoxetin
Fluoxetina
Fluoxetina [INN-Spanish]
Fluoxetina [Spanish]
fluoxetine
Fluoxetine
Fluoxétine
fluoxetine (Prozac)
Fluoxetine (TN)
Fluoxetine (USAN/INN)
Fluoxetine [USAN:INN:BAN]
Fluoxetine Hcl
|
Fluoxetine hydrochloride
Fluoxetine Hydrochloride
Fluoxetinum
Fluoxetinum [INN-Latin]
Fluval
Fontex
Foxetin
HMS2090H14
KBio1_001763
KBio2_002159
KBio2_004727
KBio2_007295
KBio3_002595
KBioGR_001166
KBioSS_002159
L000931
Lilly-110140
Lopac0_000558
LS-31040
Methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine
Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine
MolPort-001-683-482
NCGC00015428-10
NCGC00024879-03
NCGC00024879-04
nchembio.534-comp2
N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine
N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
NSC283480
Portal
Prestwick0_000511
Prestwick1_000511
Prestwick2_000511
Prestwick3_000511
Prozac
Prozac Weekly
Pulvules
Reconcile
Reneuron
Sarafem
SPBio_001815
SPBio_002382
SpecPlus_000723
Spectrum_001679
Spectrum2_001658
Spectrum3_001648
Spectrum4_000613
Spectrum5_001518
STK734483
Symbyax
TL8003595
UNII-01K63SUP8D
|
|
40 |
|
Clopidogrel |
Approved |
Phase 2 |
|
113665-84-2, 120202-66-6 |
60606 |
Synonyms:
( )-(S)-Clopidogrel
(+)-(S)-Clopidogrel
(+)-Clopidogrel
(S)-Clopidogrel
(S)-Methyl 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate
113665-84-2
AC-19024
AC1L1TKZ
AC1Q41I9
BIDD:GT0284
BMS Brand 1 OF clopidogrel bisulfate
BMS Brand 2 OF clopidogrel bisulfate
BRD-K27721098-065-02-9
BSPBio_003211
C16H16ClNO2S
CGE
CHEBI:37941
CHEMBL1771
CID60606
clopidogrel
Clopidogrel
Clopidogrel (INN)
Clopidogrel (TN)
Clopidogrel [Ban:Inn]
Clopidogrel [BAN:INN]
Clopidogrel [INN:BAN]
Clopidogrel besylate
Clopidogrel bisulfate
Clopidogrel bisulphate
Clopidogrel hydrochloride
Clopidogrel napadisilate
Clopidogrel sandoz
Clopidogrel sulfate
CLOPIDOGREL SULFATE
clopidogrel, (+)(S)-isomer
Clopidogrel, (+)(S)-isomer
Clopidogrel-mepha
Clopidogrelum
CPD000550475
D07729
DB00758
|
DivK1c_000787
HMS2090O21
HMS502H09
HSDB 7430
IDI1_000787
Iscover
Isocover
KBio1_000787
KBio2_000545
KBio2_003113
KBio2_005681
KBio3_002431
KBioGR_000689
KBioSS_000545
LS-172232
Methyl (+)-(S)-alpha-(o-chlorophenyl)-6,7-dihydrothieno(3,2-c)pyridine-5(4H)-acetate
methyl (2S)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)ethanoate
methyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate
MLS001165708
MLS001195633
MLS001304711
MolPort-002-885-817
MolPort-003-845-991
NCGC00163329-02
nchem.651-comp8
NINDS_000787
Plavix
Plavix (TN)
SAM002589956
SMR000550475
SPBio_000463
Spectrum_000105
Spectrum2_000512
Spectrum3_001606
Spectrum4_000175
SR 25990
STK580572
STOCK5S-27782
TL8000400
UNII-A74586SNO7
Zyllt
|
|
41 |
|
Aspirin |
Approved, Vet_approved |
Phase 2 |
|
50-78-2 |
2244 |
Synonyms:
11126-35-5
11126-37-7
1oxr
2-(ACETYLOXY)benzoate
2-(ACETYLOXY)benzoIC ACID
2349-94-2
26914-13-6
2-Acetoxybenzenecarboxylate
2-Acetoxybenzenecarboxylic acid
2-Acetoxybenzoate
2-Acetoxybenzoic acid
2-Carboxyphenyl acetate
50-78-2
8-hour Bayer
98201-60-6
A 5376
A.S.A
A.S.A.
A.S.A. empirin
A.S.A. Empirin
A2093_SIGMA
A3160_SIGMA
A5376_SIGMA
A6810_SIGMA
AB1003266
AC 5230
AC1L1D8U
AC1Q1LA0
Acenterine
Acesal
Acetal
Acetard
Aceticyl
Acetilsalicilico
Acetilum acidulatum
Acetisal
Acetol
Acetonyl
Acetophen
Acetosal
Acetosalic acid
Acetosalin
Acetoxybenzoic acid
Acetylin
Acetylsal
Acetylsalicylate
Acetylsalicylic acid
ACETYLSALICYLIC ACID
Acetylsalicylsaeure
Acetylsalicylsaure
Acetylsalicylsäure
Acetylsalycilic acid
Acetyonyl
Acetysal
Acetysalicylic acid
Acid, acetylsalicylic
Acide 2-(acetyloxy)benzoique
acide 2-(acétyloxy)benzoïque
Acide acetylsalicylique
Acide acétylsalicylique
acido Acetilsalicilico
Acido acetilsalicilico
ácido acetilsalicílico
Acido O-acetil-benzoico
Acidum acetylsalicylicum
Acimetten
Acisal
Acylpyrin
Adiro
AI3-02956
AIN
AKOS000118884
Aloxiprimum
ASA
Asacard
Asagran
Asatard
Ascoden-30
Aspalon
Aspec
Aspergum
Aspirdrops
aspirin
Aspirin
Aspirin (JP15/USP)
Aspirin [BAN:JAN]
Aspirina
Aspirina 03
Aspirine
Aspir-Mox
Asprin
Aspro
Aspro Clear
Asteric
Azetylsalizylsaeure
Azetylsalizylsäure
Bay-e-4465
Bayer
Bayer Aspirin 8 Hour
Bayer Buffered
Bayer Extra Strength Aspirin For Migraine Pain
Bayer Plus
Benaspir
Bialpirina
Bialpirinia
BIDD:GT0118
Bi-prin
BRN 0779271
Bufferin
C01405
Caprin
Cardioaspirin
Cardioaspirina
CCRIS 3243
Cemirit
CHEBI:15365
CHEMBL25
CID2244
Claradin
Clariprin
cMAP_000006
Colfarit
component of Midol
component of Synirin
Contrheuma retard
Coricidin
Crystar
D00109
D001241
DB00945
Decaten
Delgesic
Dispril
DivK1c_000555
Dolean pH 8
Duramax
Easprin
Easprin (TN)
ECM
Ecolen
Ecotrin
EINECS 200-064-1
Empirin
|
Empirin with Codeine
Endosprin
Endydol
Entericin
Enterophen
Enterosarein
Enterosarine
Entrophen
EU-0100038
Extren
Globentyl
Globoid
Helicon
HMS1920E13
HMS2090G03
HMS2091K13
HMS501L17
HSDB 652
I14-7505
IDI1_000555
Idragin
Istopirin
Kapsazal
KBio1_000555
KBio2_001725
KBio2_002271
KBio2_004293
KBio2_004839
KBio2_006861
KBio2_007407
KBio3_002149
KBio3_002751
KBioGR_000398
KBioGR_002271
KBioSS_001725
KBioSS_002272
Kyselina 2-acetoxybenzoova
Kyselina acetylsalicylova
Levius
Lopac0_000038
Lopac-A-5376
LS-143
Magnecyl
Measurin
Medisyl
Micristin
MLS001055329
MLS001066332
MLS001336045
MLS001336046
MolPort-000-871-622
NCGC00015067-01
NCGC00015067-04
NCGC00015067-09
NCGC00090977-01
NCGC00090977-02
NCGC00090977-03
NCGC00090977-04
NCGC00090977-05
NCGC00090977-06
NCGC00090977-07
nchem.859-comp6
NCI60_002222
Neuronika
NINDS_000555
Novid
NSC 27223
NSC27223
NSC406186
Nu-seals
Nu-seals aspirin
O-(Acetyloxy)benzoate
O-(Acetyloxy)benzoic acid
O-accetylsalicylic acid
O-Acetoxybenzoate
o-acetoxybenzoic acid
o-Acetoxybenzoic acid
O-Acetoxybenzoic acid
O-Acetylsalicylate
O-acetylsalicylic acid
O-Acetylsalicylic acid
o-carboxyphenyl acetate
o-Carboxyphenyl acetate
O-Carboxyphenyl acetate
O-Carboxyphenyl acetic acid
Persistin
Pharmacin
Pirseal
PL-2200
Polopirin
Polopiryna
Premaspin
R16CO5Y76E [UNII]
Rheumin tabletten
Rheumintabletten
Rhodine
Rhonal
Ronal
S-211
Salacetin
Salcetogen
Saletin
Salicylate acetate
Salicylic acid acetate
Salicylic acid acetic acid
Salicylic acid, acetate
Salospir
SMR000059138
Solfrin
Solprin
Solprin acid
Solpyron
Solupsan
SP 189
SPBio_001838
Spectrum_001245
SPECTRUM1500130
Spectrum2_001899
Spectrum3_001295
Spectrum4_000099
Spectrum5_000740
Spira-Dine
St. Joseph
St. Joseph Aspirin for Adults
ST075414
Supac
Tasprin
Temperal
Toldex
Triaminicin
Triple-sal
UNII R16CO5Y76E
UNII=R16CO5Y76E
UNII-R16CO5Y76E
UNM-0000306102
Vanquish
WLN: QVR BOV1
Xaxa
XAXA
Yasta
Zorprin
ZORprin
|
|
42 |
|
Tacrolimus |
Approved, Investigational |
Phase 2 |
|
104987-11-3 |
445643 439492 6473866 |
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
Advagraf
AKOS005145901
Ambap104987-11-3
Ambap5429
Anhydrous tacrolimus
Anhydrous, tacrolimus
BCBcMAP01_000194
Bio-0921
Bio2_000470
Bio2_000950
BRD-K35452788-001-02-1
BSPBio_001279
BSPBio-001279
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
Cilag brand OF tacrolimus
CPD000466356
CPD-10016
D08556
DB00864
DivK1c_001040
FK 506
FK5
Fk-506
FK506
FK-506
FR 900506
FR900506
|
FR-900506
FT-0082660
Fujimycin
Fujisawa brand OF tacrolimus
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
IDI1_001040
IDI1_002225
Janssen brand OF tacrolimus
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
nchembio.2007.23-comp2
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Prograft
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
tacrolimus
Tacrolimus
Tacrolimus (anhydrous)
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus anhydrous
tacrolimus hydrate
Tacrolimus, anhydrous
Tsukubaenolide
UNII-Y5L2157C4J
|
|
43 |
|
Dopamine |
Approved |
Phase 2 |
|
51-61-6, 62-31-7 |
681 |
Synonyms:
(3H)-Dopamine
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-dihydroxyphenyl)ethylamine
2-(3,4-Dihydroxyphenyl)ethylamine
2-benzenediol
3,4 Dihydroxyphenethylamine
3,4-dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-aminoethyl)catechol
4-(2-Aminoethyl)catechol
4-(2-aminoethyl)pyrocatechol
4-(2-aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
a-(3,4-Dihydroxyphenyl)-b-aminoethane
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL 279
BIDD:ER0506
Biomol-NT_000001
BPBio1_001123
BSPBio_001932
C03758
CHEBI:18243
CHEMBL59
CID681
cMAP_000036
cMAP_000065
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
dopamine
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopamine hydrochloride
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydrochloride, dopamine
|
Hydroxytyramin
hydroxytyramine
Hydroxytyramine
IDI1_000780
intropin
Intropin
Intropin [*hydrochloride*]
IP 498
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L000232
L-DOPAMINE
LDP
Lopac0_000586
Lopac-H-8502
LS-159
Medopa (TN)
m-Hydroxytyramine hydrochloride
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
Spectrum_001012
SPECTRUM1505155
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
ST048774
STK301601
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
|
|
44 |
|
Tamoxifen |
Approved |
Phase 2 |
|
10540-29-1 |
2733526 |
Synonyms:
(Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene
(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
(Z)-2-(Para-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
(Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC)
(Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE
(Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
,citrate
10540-29-1
1-p-.beta.-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-b-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-β-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-P-b-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-P-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-P-β-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1ya4
2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine
54965-24-1 (citrate)
AC1MBZ3R
apo-Tamox
Apo-Tamox
BIDD:ER0008
BIDD:GT0009
BIDD:PXR0003
BPBio1_000278
BRD-K93754473-001-02-9
BRD-K93754473-048-05-3
BSPBio_000252
BSPBio_001150
BSPBio_001982
C07108
C26H29NO
CCRIS 3275
CHEBI:41774
CHEMBL83
CID2733526
Citofen
Citrate, tamoxifen
cMAP_000044
Crisafeno
D08559
DB00675
Diemon
EINECS 234-118-0
Gen-tamoxifen
Gen-Tamoxifen
HMS1362J11
HMS1792J11
HMS1990J11
HMS2090N08
HSDB 6782
ICI 47699
ICI-46,474
ICI-47699
IDI1_000258
IDI1_002170
Istubol
Kessar
L024126
Lopac0_001203
LS-393
MLS001332535
MLS001332536
|
MolPort-003-850-384
NCGC00024928-01
NCGC00024928-03
NCGC00024928-04
NCGC00024928-05
NCGC00024928-07
NCGC00024928-08
NCGC00024928-09
NCGC00024928-12
nchembio.140-comp7
nchembio.76-comp1
nchembio732-comp3
Noltam
Nolvadex
Nolvadex-D
Nourytam
Novaldex
Novo-Tamoxifen
NSC727681
Oncomox
Pms-Tamoxifen
PMS-Tamoxifen
Prestwick2_000146
Prestwick3_000146
QTL1_000079
Retaxim
Savient brand OF tamoxifen citrate
SMR000059172
Soltamox
Spectrum5_001417
Spectrum5_002043
ST50511785
T5648_SIGMA
Tamizam
Tamofen
Tamone
Tamoplex (TN)
Tamoxasta
Tamoxen
tamoxifen
Tamoxifen
Tamoxifen (INN)
TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1))
Tamoxifen (TN)
Tamoxifen (Z)
Tamoxifen [INN:BAN]
Tamoxifen and its salts
Tamoxifen citrate
Tamoxifen Citrate
Tamoxifene
Tamoxifène
Tamoxifene [INN-French]
Tamoxifeno
Tamoxifeno [INN-Spanish]
Tamoxifenum
Tamoxifenum [INN-Latin]
Tocris-0999
Tomaxithen
TRANS FORM OF TAMOXIFEN
trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
trans-Tamoxifen
Trans-Tamoxifen
UNII-094ZI81Y45
UPCMLD-DP027
Valodex
Zemide
Zitazonium
|
|
45 |
|
Olaparib |
Approved |
Phase 1, Phase 2 |
|
763113-22-0 |
23725625 |
Synonyms:
4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one
4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one
4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
763113-22-0
937799-91-2
Acylpiperazine analogue, 47
AKOS005145764
AZD 2281
AZD2281
AZD-2281
|
CHEMBL521686
EC-000.2324
EN002690
FT-0083489
KU-0059436
KU-59436
olaparib
Olaparib
Olaparib, KU-0059436, AZD2281, KU0059436, AZD2281
S1060_Selleck
|
|
46 |
|
Bevacizumab |
Approved, Investigational |
Phase 1, Phase 2 |
|
216974-75-3 |
|
Synonyms:
216974-75-3
antiVEGF
Anti-VEGF Humanized Monoclonal Antibody
anti-VEGF monoclonal antibody
Anti-VEGF monoclonal antibody
Avastin
Avastin (TN)
bevacizumab
|
Bevacizumab
Bevacizumab (genetical recombination)
Bevacizumab (genetical recombination) (JAN)
bevacizumab-awwb
D06409
R-435
rhuMAb-VEGF
|
|
47 |
|
Selexipag |
Approved |
Phase 2 |
|
475086-01-2 |
|
Synonyms:
|
48 |
|
Ubenimex |
Investigational |
Phase 2 |
|
58970-76-6 |
|
Synonyms:
|
49 |
|
Cicletanine |
Investigational |
Phase 2 |
|
89943-82-8 |
|
50 |
|
Narcotics |
|
Phase 2 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 304)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Hemodynamic Evaluation of Patients With Pulmonary Arterial Hypertension. Response to Sildenafil Treatment |
Unknown status |
NCT00483626 |
Phase 4 |
oral sildenafil |
2 |
Intravenous Iron Treatment In Iron Deficient Patients With Idiopathic Pulmonary Arterial Hypertension |
Unknown status |
NCT01288651 |
Phase 4 |
Ferricarboxymaltose |
3 |
Randomized Controlled Trial to Compare the Efficacy of Combination Therapy vs Monotherapy for Pulmonary Arterial Hypertension in Systemic Sclerosis |
Unknown status |
NCT03053739 |
Phase 4 |
Sildenafil 20mg and Bosentan 62.5mg;Sildenafil 20mg and Placebo |
4 |
Raising the Bars in the Treatment of Pulmonary Arterial Hypertension: Goal Oriented Strategy to Preserve Ejection Fraction Trial |
Unknown status |
NCT03236818 |
Phase 4 |
ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan) |
5 |
An Open-label Extension of Study AC-066A401 Investigating the Safety and Tolerability of ACT-385781A Compared to Flolan® in Injectable Prostanoid Treatment-naïve Patients With Pulmonary Arterial Hypertension (PAH) |
Completed |
NCT01105117 |
Phase 4 |
ACT-385781A (Actelion Epoprostenol);Flolan® |
6 |
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Tracleer (Bosentan) on Oxygen Saturation and Cardiac Hemodynamics in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology |
Completed |
NCT00317486 |
Phase 4 |
bosentan |
7 |
TRUST-2: An Open-label Continuation Trial of the Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH) |
Completed |
NCT03055221 |
Phase 4 |
Intravenous Treprostinil |
8 |
A Multinational, Multicentre, Randomized, Double-blind Study To Assess The Efficacy And Safety Of Oral Sildenafil 20mg Tid Or Placebo When Added To Bosentan In The Treatment Of Subjects, Aged 18 Years And Above, With Pulmonary Arterial Hypertension (Pah) |
Completed |
NCT00323297 |
Phase 4 |
Bosentan;Bosentan;Sildenafil Citrate |
9 |
A Phase IV, Open-label, Randomized, Multicenter Study of the Safety, Tolerability,and Pharmacokinetics of ACT- 385781A Compared to Flolan® in Injectable Prostanoid Treatment-naïve Patients With Pulmonary Arterial Hypertension (PAH) |
Completed |
NCT01105091 |
Phase 4 |
ACT-385781A (Actelion Epoprostenol);Flolan® |
10 |
Phase IV Study of Chronic Infusional Epoprostenol for Severe Primary Pulmonary Hypertension |
Completed |
NCT00004754 |
Phase 4 |
epoprostenol |
11 |
An Open Label, Multi-center Study Evaluating the Safety of Long-term Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis® (Iloprost) in Subjects With Pulmonary Arterial Hypertension. |
Completed |
NCT00741819 |
Phase 4 |
Inhaled treprostinil |
12 |
A Prospective, Multicenter, Single-arm, Open-label, Phase 4 Study to Evaluate the Effects of Macitentan on Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension Assessed by Cardiac Magnetic Resonance Imaging |
Completed |
NCT02310672 |
Phase 4 |
Macitentan |
13 |
An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Patients With Exercise Induced Pulmonary Arterial Hypertension |
Completed |
NCT01338636 |
Phase 4 |
Ambrisentan |
14 |
COMPASS 3: An Open-label, Multi-Center Study Employing a Targeted 6-Minute Walk Test (6-MWT) Distance Threshold Approach to Guide Bosentan-Based Therapy and to Assess the Utility of Magnetic Resonance Imaging (MRI) on Cardiac Remodeling |
Completed |
NCT00433329 |
Phase 4 |
Bosentan;Sildenafil |
15 |
Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Patients With Pulmonary Arterial Hypertension - A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Prospective, Event Driven Phase IV Study |
Completed |
NCT00303459 |
Phase 4 |
bosentan;placebo |
16 |
A Phase 3, Multi-center, Open-label Study To Investigate Safety, Efficacy, And Tolerability Of Sildenafil Citrate In Pediatric Patients With Pulmonary Arterial Hypertension |
Completed |
NCT01642407 |
Phase 4 |
Sildenafil |
17 |
A Multi-center, Double-blind, Placebo-controlled Phase 4 Study in Patients With Pulmonary Arterial Hypertension to Assess the Effect of Selexipag on Daily Life Physical Activity and Patient's Self-reported Symptoms and Their Impacts |
Completed |
NCT03078907 |
Phase 4 |
Selexipag;Placebo |
18 |
A Multi-Center, Open-Label Extension Study to Protocol AC-052-405 to Evaluate the Safety and Efficacy of Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology |
Completed |
NCT00367770 |
Phase 4 |
Tracleer® |
19 |
A Prospective, Randomized, International, Multicenter, Double-arm, Controlled, Open-label Study of Riociguat in Patients With Pulmonary Arterial Hypertension (PAH) Who Are on a Stable Dose of Phosphodiesterase-5 Inhibitors (PDE-5i) With or Without Endothelin Receptor Antagonist (ERA), But Not at Treatment Goal |
Completed |
NCT02891850 |
Phase 4 |
Adempas (Riociguat, BAY63-2521);Sildenafil;Tadalafil |
20 |
A 16 Week, Open Label, Multi-centre, Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of a Rapid Dose Titration Regimen of Subcutaneous Remodulin® Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) |
Completed |
NCT02847260 |
Phase 4 |
Remodulin |
21 |
An Open-label, Multicenter Study of Ambrisentan and a Phosphodiesterase Type-5 Inhibitor Combination Therapy in Subjects With Pulmonary Arterial Hypertension Who Have Demonstrated a Sub-Optimal Response to a Phosphodiesterase Type-5 Inhibitor |
Completed |
NCT00617305 |
Phase 4 |
Ambrisentan;Placebo;Sildenafil;Tadalafil |
22 |
A Multicenter, Randomized, Parallel Placebo-Controlled Study of the Safety and Efficacy of Subcutaneous Remodulin® Therapy After Transition From Flolan® in Patients With Pulmonary Arterial Hypertension |
Completed |
NCT00058929 |
Phase 4 |
treprostinil sodium |
23 |
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis |
Completed |
NCT01042158 |
Phase 4 |
tadalafil and ambrisentan upfront combination therapy |
24 |
A MULTINATIONAL, MULTICENTER STUDY TO ASSESS THE EFFECTS OF ORAL SILDENAFIL ON MORTALITY IN ADULTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) |
Recruiting |
NCT02060487 |
Phase 4 |
sildenafil citrate;sildenafil citrate;sildenafil citrate |
25 |
EXPEDITE: A 16-Week, Multicenter, Open-label Study of Remodulin Induction Followed by Orenitram Optimization in Subjects With Pulmonary Arterial Hypertension |
Recruiting |
NCT03497689 |
Phase 4 |
Intravenous/Subcutaneous Treprostinil; Oral Treprostinil |
26 |
A Prospective, Multicenter, Single-Arm, Open-Label, Phase 4 Study of the Effects of Selexipag on Right Ventricular Remodeling in Pulmonary Arterial Hypertension Assessed by Cardiac Magnetic Resonance Imaging |
Not yet recruiting |
NCT04435782 |
Phase 4 |
JNJ-67896049 |
27 |
Spironolactone Therapy in Chronic Stable Right HF Trial |
Suspended |
NCT03344159 |
Phase 4 |
Spironolactone;Placebo |
28 |
Combination Therapy of Bosentan and Aerosolized Iloprost in Idiopathic Pulmonary Arterial Hypertension |
Terminated |
NCT00120380 |
Phase 4 |
Aerosolized iloprost;Placebo |
29 |
A Multinational, Multicentre, Randomized, Parallel Group, Double-Blind Study To Assess The Efficacy and Safety Of 1 mg, 5 mg and 20 mg TID of Oral Sildenafil in the Treatment of Subjects Aged 18 Years and Over With Pulmonary Arterial Hypertension (PAH) |
Terminated |
NCT00430716 |
Phase 4 |
Sildenafil citrate;Sildenafil citrate;Sildenafil citrate;Sildenafil citrate |
30 |
Prospective, Multicenter, Open-label Study Evaluating the Effects of First-line Oral Combination Therapy of Macitentan and Tadalafil in Patients With Newly Diagnosed Pulmonary Arterial Hypertension (OPTIMA). |
Terminated |
NCT02968901 |
Phase 4 |
macitentan;tadalafil |
31 |
Treprostinil for Untreated Symptomatic PAH Trial: A 12-Week Multicenter Randomized Double-Blind Placebo-Controlled Trial of the Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension |
Terminated |
NCT00494533 |
Phase 4 |
Remodulin (treprostinil sodium) |
32 |
A Safety and Clinical Efficacy Study Measuring Echocardiographic Composite Comparing Ambrisentan (Letairis®) After a Switch From Bosentan (Tracleer®) or Macintentan (Opsumit®) in Treatment of Pulmonary Arterial Hypertension (PAH) |
Terminated |
NCT02885012 |
Phase 4 |
Ambrisentan |
33 |
The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study (The CAPS-PAH Study) |
Terminated |
NCT02253394 |
Phase 4 |
Ambrisentan plus Spironolactone;Ambrisentan plus Placebo |
34 |
Rapid Switch From Intravenous Epoprostenol to Intravenous Remodulin® (Treprostinil Sodium) Using the Crono Five Ambulatory Infusion Pump in Patients With Stable Pulmonary Arterial Hypertension (PAH): Safety, Efficacy and Treatment Satisfaction |
Terminated |
NCT00439946 |
Phase 4 |
treprostinil |
35 |
Randomized Placebo Controlled Trial of Treprostinil Infusion Combined With Oral Tadalafil or Placebo in Pulmonary Arterial Hypertension |
Terminated |
NCT01302444 |
Phase 4 |
Tadalafil;Placebo |
36 |
Treatment of Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Hypertension With Bosentan: A Single Center Pilot Study |
Withdrawn |
NCT00625469 |
Phase 4 |
bosentan |
37 |
Combined Use of Angiography, Optical Coherence Tomography and Intravascular Ultrasound in Evaluation of Pulmonary Vascular Structure and Function in Patients With Pulmonary Arterial Hypertension Treated With Oral Bosentan |
Withdrawn |
NCT01508780 |
Phase 4 |
|
38 |
A 16-Week, Open-Label, Multi-Center, Parallel, Randomized Controlled Study to Compare the Safety, Tolerability, Pharmacokinetics and Efficacy of Slow and Rapid Dose Titration Regimens of Subcutaneous Remodulin Therapy in Subjects With Pulmonary Arterial Hypertension |
Withdrawn |
NCT02893995 |
Phase 4 |
Slow Dose Titration Group of Subcutaneous Treprostinil;Rapid Dose Titration Group of Subcutaneous Treprostinil |
39 |
An Open-Label Extension Trial to Evaluate the Safety of Continued Therapy With Subcutaneous Remodulin® in Subjects With Pulmonary Arterial Hypertension Who Completed Study CVT-CV-003 |
Withdrawn |
NCT02882126 |
Phase 4 |
Subcutaneous Treprostinil |
40 |
Phase â…¢ Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Arterial Hypertension Patients |
Unknown status |
NCT01712997 |
Phase 3 |
Iloprost;Bosentan |
41 |
A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension |
Completed |
NCT00709956 |
Phase 3 |
iloprost (5 µg);placebo |
42 |
An Open Label, Multicenter Study to Assess the Pharmacokinetics, Tolerability, and Safety of a Pediatric Formulation of Bosentan in Children With Idiopathic or Familial Pulmonary Arterial Hypertension |
Completed |
NCT00319267 |
Phase 3 |
Bosentan |
43 |
An Open Label, Long-term, Safety, and Tolerability Extension Study Using the Pediatric Formulation of Bosentan in the Treatment of Children With Idiopathic or Familial Pulmonary Arterial Hypertension Who Completed FUTURE 1 |
Completed |
NCT00319020 |
Phase 3 |
Bosentan |
44 |
A Multicenter, Double-blind, Randomized Study Comparing the Safety and Tolerability of Iloprost Inhalation Solution Delivered by I-neb Utilizing Power Disc-15 and Power Disc-6 in Patients With Symptomatic Pulmonary Arterial Hypertension |
Completed |
NCT00709098 |
Phase 3 |
iloprost;iloprost |
45 |
Ambrisentan in PAH - A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects With Pulmonary Arterial Hypertension. |
Completed |
NCT00423202 |
Phase 3 |
ambrisentan |
46 |
A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of the Six Months Treatment With the Tyrosine Kinase Inhibitor STI571 for the Treatment of Pulmonary Arterial Hypertension (PAH) |
Completed |
NCT00477269 |
Phase 2, Phase 3 |
Imatinib mesylate;Placebo |
47 |
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension |
Completed |
NCT01106014 |
Phase 3 |
Selexipag;Placebo |
48 |
A Non-randomized, Multiple Dose, Three Treatment Period, Open-label, Single Sequence, Single Group Study to Evaluate the Pharmacokinetic Effect of Two Doses of QTI571 (Imatinib) on the Co-administered Drugs Sildenafil and Bosentan in Pulmonary Arterial Hypertension (PAH) Patients |
Completed |
NCT01392469 |
Phase 3 |
Imatinib |
49 |
An Open-label Extension of Study AC-066A301 Investigating the Safety and Tolerability of ACT-385781A in Patients With Pulmonary Arterial Hypertension (PAH) |
Completed |
NCT01470144 |
Phase 3 |
Epoprostenol |
50 |
Ambrisentan in PAH - A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects With Pulmonary Arterial Hypertension |
Completed |
NCT00423748 |
Phase 3 |
ambrisentan |
|